7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
Rybelsus is not FDA-approved for adolescents ages 12 to 17, but off-label prescribing is increasing. Learn what the evidence shows, what guidelines say, and how clinicians approach dosing, monitoring, and shared decision-making in this age group.
An evidence-based review of oral semaglutide (Rybelsus) in children under 12, including FDA status, the completed pediatric trial, current evidence gaps, and approved alternatives.
A guide covering how caregivers should administer oral semaglutide (Rybelsus) to adolescents ages 12 to 17, including dosing schedules, fasting rules, missed-dose protocols, and safety monitoring.
Complete caregiver guide to administering oral semaglutide (Rybelsus) in adults 65 and older, covering dosing rules, swallowing difficulties, hypoglycemia risk, monitoring, and when to call the prescriber.
A guide to oral semaglutide (Rybelsus) use in adolescents ages 12 to 17, covering growth, puberty, bone density, weight outcomes, and current FDA status.
A guide to prescribing oral semaglutide (Rybelsus) in patients aged 65 and older, covering dose titration, renal and cardiac considerations, fall-risk, and how to transition geriatric patients smoothly into standard adult-care protocols.
A guide covering what parents, teachers, and caregivers need to know about oral semaglutide (Rybelsus) dosing schedules, nausea management, physical education, and hypoglycemia planning for children under age 12.